Acute myeloid leukemia (AML) is a hematopoietic malignancy that is characterized by the accumulation of malignant blasts in the bone marrow and peripheral blood.1,2 Disease pathogenesis is driven by the accumulation of genetic modifications, including chromosomal abnormalities and somatic mutations, that alter the epigenetic landscape, gene expression, and cellular function.1-4
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated
Liesveld JL, Lichtman MA. In: Lichtman MA, et al. Williams Hematology. 7th ed. New York, NY: McGraw-Hill; 2005.
Conway O’Brien E, et al. Adv Hematol. 2014;2014:103175. PMID: 24778653
Licht JD, et al. Hematology Am Soc Hematol Educ Program. 2005:137-142. PMID: 16304371
To view To return to www.researchoncology.com